[Abstract]Objective To explore the clinical effect of Sacubitril Valsartan in treatment of heart failure with reduced left ventricular ejection fraction (LVEF).Methods A total of 80 heart failure patients with reduced left ventricular ejection fraction who were admitted in Pingxiang People′s Hospital from January 2019 to January 2020 were selected as the research subjects and divided into two groups according to random number table method,with 40 cases in each group.The control group was received routine anti-heart failure treatment,and the observation group was treated with Sacubitril Valsartan instead of angiotensin converting enzyme inhibitor and angiotensin Ⅱreceptor blocker (ACEI/ARB).Serum levels of the neuroendocrine system (norepinephrine [NE],aldosterone,angiotensin Ⅱ[AngⅡ],N-terminal probrain natriuretic peptide [NT-proBNP]),cardiac structure (left ventricular end-systolic dimension [LVESD],left ventricular end-diastolic dimension [LVEDD],LVEF) and the Minnesota heart failure quality of life (MHFQL) score were compared between the two groups before treatment and after treatment for 3 months.Results There were no statistical differences in the serum content of neuroendocrine system,cardiac structure,and quality of life between the two groups before treatment (P＞0.05).The NE,aldosterone,AngⅡ,LVESD,LVEDD,NT-proBNP,MHFQL scores in the two groups after treatment for 3 months were higher than those before treatment,and the LVEF was lower than that before treatment；the NE,aldosterone,AngⅡ,LVESD,LVEDD,NT-proBNP and MHFQL scores in the observation group were lower than those in the control group,and the LVEF in the observation group was higher than that in the control group,and the differences were statistically significant (P＜0.05).Conclusion Sacubitril valsartan in treatment of heart failure patients with reduced LVEF can inhibit over-activation of neuroendocrine,prevent and reverse cardiovascular remodeling,increase LVEF,and improve quality of life.